Our research interest is in the regenerative medicine for retinal diseases. Currently, there is no effective solution to reverse retina degeneration that leads to blindness.

One of our aims is to develop stem cell based therapy for the treatment of retinal diseases such as Aged Macular Degeneration and Aging Glaucoma.

We have generated retina specific laminin isoforms and have used them to recapitulate the in vivo retina extracellular matrix niche environment.

This mimetic retina matrix has shown efficiency in the retinal differentiation from human embryonic stem cells to generate photoreceptors, retinal pigmented epithelium and ganglion cells.

Our patented novel technology is highly reproducible, xeno-free and chemically defined, building towards our goal in producing clinically safe and functional retinal cells to treat vision loss.

By making use of this retina platform, we are also interested to study inherited retinal diseases through the modelling of normal and disease retina.

By expanding our understanding in retina diseases, we hope to contribute to the development of effective therapeutics to treat vision loss.